US regulator approves pill form of Wegovy weight-loss drug

Wegovy becomes first pill of its kind to be approved, shifting weight-loss drugs beyond injections.

Understanding the nuances of general health requires a comprehensive approach that considers both individual circumstances and broader medical research. Medical professionals emphasize the importance of personalized care and evidence-based practices when addressing health concerns.

Recent studies have shed light on various aspects of general health, providing new insights that can help individuals make informed decisions about their health. It's essential to consult with qualified healthcare providers who can offer guidance tailored to your specific needs and medical history.

When considering treatment options or lifestyle changes related to general health, it's important to weigh the potential benefits against any risks. Open communication with your healthcare team ensures that you receive the most appropriate care and support throughout your health journey.

Preventive measures and early intervention play crucial roles in maintaining optimal health outcomes. Staying informed about the latest research and recommendations in general health can empower you to take proactive steps toward better health and well-being.

The US Food and Drug Administration (FDA) has approved a pill version of the weight-loss drug Wegovy, according to pharmaceutical giant Novo Nordisk.

It is the first pill of its kind to receive approval from the regulator, marking a new era for weight-loss drugs.

Wegovy's Danish makers Novo Nordisk said the once-daily pill was a "convenient option" to the injectable and would provide the same weight loss as the shot. It comes after Wegovy was approved by the FDA specifically for weight loss.

Others like Ozempic, which has similar weight-loss effects, were primarily approved for the treatment of Type 2 diabetes.

The Wegovy pill showed an average weight loss of 16.6% during Novo Nordisk's trials, the firm said on Monday.

A third of around 1,300 participants experienced 20% or greater weight loss in the same trial, it added.

The pill is expected to be launched in the US in early January 2026.

"Patients will have a convenient, once-daily pill that can help them lose as much weight as the original Wegovy injection," said Mike Doustdar, the firm's chief executive.

The pill version of Wegovy could give Novo Nordisk's sales a boost after a challenging year which saw its shares slide as it warned over its profits.

The company has faced intense competition in the weight-loss market from rival drugmakers like Eli Lilly.

Novo Nordisk's shares rose by almost 10% in after-hours trade in New York after the announcement.

The hub is the first of its kind in Wales and helps young people experiencing emotional difficulties.

President Donald Trump has previously accused the Nigerian government of failing to protect Christians from jihadist groups.

A coroner raises concerns over a man's treatment by Sheffield medical professionals before he died.

Imran Ahmed was among five people accused of seeking to "coerce" US firms into censoring free speech.

Cherry Cantrell has been using a light box to help reduce the symptoms of Seasonal Affective Disorder.